CUMYL-4CN-BINACA, also known as CUMYL-CYBINACA or SGT-78, is an indazole-3-carboxamide-based synthetic cannabinoid that has been distributed online as a designer drug. This compound acts as a potent agonist for CB1 and CB2 cannabinoid receptors, with EC50 values of 0.58 nM and 6.12 nM, respectively, as demonstrated in in vitro studies.
In animal models, CUMYL-4CN-BINACA has been observed to induce hypothermic and pro-convulsant effects by activating the CB1 receptor. Anecdotal reports from human users suggest that an effective dose is approximately 0.1 mg.
Of concern is the metabolism of CUMYL-4CN-BINACA, which can produce cyanide, potentially posing risks of liver toxicity. Additionally, there is a documented case of an individual experiencing hyperthermia, rhabdomyolysis, and kidney failure associated with its use, underscoring the potential dangers linked to this synthetic cannabinoid. It is essential to exercise caution and be aware of potential health risks when dealing with substances like CUMYL-4CN-BINACA.

IUPAC name
CAS Number1631074-54-8
PubChem CID117650402
CompTox Dashboard (EPA)DTXSID401009982
Chemical and physical data
Molar mass360.461 g·mol−1


  • What is CUMYL-4CN-BINACA?
  • CUMYL-4CN-BINACA, also known as CUMYL-CYBINACA or SGT-78, is a synthetic cannabinoid that has been sold online as a designer drug. It interacts with the cannabinoid receptors CB1 and CB2 in the endocannabinoid system.
  • What are the effects of CUMYL-4CN-BINACA?
  • In mice, CUMYL-4CN-BINACA has been shown to produce hypothermic and pro-convulsant effects through the CB1 receptor. Anecdotal reports suggest it has an active dose of around 0.1 mg in humans, but its impact on humans is not well-documented.
  • Are there any reported health risks associated with CUMYL-4CN-BINACA?
  • Yes, there is one reported case of hyperthermia, rhabdomyolysis, and kidney failure associated with the use of CUMYL-4CN-BINACA. Additionally, this synthetic cannabinoid can be metabolized to produce cyanide, which raises concerns about potential liver toxicity.
  • Is CUMYL-4CN-BINACA legal?
  • The legal status of CUMYL-4CN-BINACA varies by country and jurisdiction. In many places, it is considered illegal due to its classification as a controlled substance. Always check your local laws and regulations.
  • Is CUMYL-4CN-BINACA safe to use?
  • The safety of CUMYL-4CN-BINACA is a subject of concern due to its potential health risks and the limited scientific information available. It is advisable to avoid using unregulated synthetic cannabinoids due to the associated dangers.
  • Can CUMYL-4CN-BINACA show up on drug tests?
  • CUMYL-4CN-BINACA is not typically included in standard drug tests. However, specialized tests may be able to detect it if screened explicitly for.
  • Where can I find more information about CUMYL-4CN-BINACA?
  • For detailed information about CUMYL-4CN-BINACA, its pharmacological properties, and potential risks, consult reputable scientific sources, healthcare professionals, or local drug enforcement agencies.


  1. Brazilian Regulation: Anvisa (Collegiate Board Resolution No. 804) in Brazil lists CUMYL-4CN-BINACA as a controlled substance. This regulation categorizes various substances under special control, including narcotics and psychotropic compounds.
  2. Chemical Information: Cayman Chemical provides chemical data and details related to CUMYL-4CN-BINACA, which can be a valuable resource for researchers and professionals.
  3. Detection and Identification: Studies by Yeter and colleagues have identified CUMYL-4CN-BINACA in plant material and quantified it in post-mortem blood samples. The research contributes to the understanding of detection methods for this synthetic cannabinoid.
  4. Metabolism Research: Investigations by Bovens et al. and Åstrand et al. have explored the metabolism of CUMYL-4CN-BINACA in human hepatocytes and urine specimens. Notably, the studies revealed the formation of free cyanide as a metabolic product, raising concerns about potential health risks.
  5. Pharmacological Effects: A study led by Kevin and published in Frontiers in Pharmacology highlights CUMYL-4CN-BINACA’s pro-convulsant properties, shedding light on its effects on the cannabinoid receptor system.
  6. European Report: The EMCDDA–Europol Joint Report discusses CUMYL-4CN-BINACA as a new psychoactive substance, providing insights into its emergence and regulation in Europe.
  7. Clinical Case: El Zahran and Gerona reported a clinical case involving a patient who experienced hyperthermia, rhabdomyolysis, and renal failure after using CUMYL-4CN-BINACA, underscoring the potential health risks associated with this synthetic cannabinoid.

Leave a Comment

Your email address will not be published. Required fields are marked *